Close
RNS Number : 8772Z
Hikma Pharmaceuticals Plc
15 January 2020
 

Annex DTR3

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons

All relevant boxes should be completed in block capital letters

1.      

Name of the Issuer:

 

Hikma Pharmaceuticals PLC

2.      

State whether the notification relates to (i) a transaction notified in accordance with DTR 3.1.2 R, (ii) a disclosure made in accordance with LR 9.8.6R(1) or (iii) a disclosure made in accordance with section 793 of the Companies Act (2006):

DTR 3.1.2 R

3.      

Name of person discharging managerial responsibilities/director:

Said Darwazah, Mazen Darwazah and Ali Al-Husry

4.      

State whether notification relates to a person connected with a person discharging managerial responsibilities/ director named in 3 and identify the connected person:

Yes:  Darhold Limited

5.      

Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a non-beneficial interest:

Beneficial interest in Darhold Limited

6.      

Description of shares (including class), debentures or derivatives or financial instruments relating to shares:

Ordinary Shares

7.      

Name of registered shareholders(s) and, if more than one, the number of shares held by each of them:

Jordan Kuwait Bank PLC

8.      

State the nature of the transaction:

Release of a pledge over 2,345,000 Ordinary Shares

9.      

Number of shares, debentures or financial instruments relating to shares acquired:

None

10.    

Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage):

N/A

11.    

Number of shares, debentures or financial instruments relating to shares disposed:

None

12.    

Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage):

N/A

13.    

Price per share or value of transaction:

N/A

14.    

Date and place of transaction:

Amman, 15 January 2020

 

15.    

Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage):

60,000,000 - 24.76 per cent.

16.    

Date issuer informed of transaction:

15 January 2020

 

If a person discharging managerial responsibilities has been granted options by the issuer complete the following boxes

17.     

Date of grant

18.  

Period during which or date on which exercisable

19.     

Total amount paid (if any) for grant of the option

20.  

Description of shares or debentures involved (class and number)

21.     

Exercise price (if fixed at time of grant) or indication that price is to be fixed at the time of exercise

22.  

Total number of shares or debentures over which options held following notification

23.     

Any additional information

24.  

Name of contact and telephone number for queries

 

Name of authorised official or issuer responsible for making notification

Peter Speirs, Company Secretary, Hikma Pharmaceuticals PLC

Date of notification:  15 January 2020

 

Notes:

This form is intended for use by an issuer to make a RIS notification required by DTR 3.1.4

(1)           An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.

(2)           An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24.

(3)           An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24.

(4)           An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHGCGDBBSBDGGU